This chemical is primarily used in the field of targeted protein degradation, specifically in the development of PROTACs (Proteolysis Targeting Chimeras). PROTACs are bifunctional molecules designed to degrade target proteins by recruiting them to an E3 ubiquitin ligase, leading to their ubiquitination and subsequent proteasomal degradation. In this context, it serves as a BRD4-binding moiety, enabling the selective targeting of BRD4, a protein involved in the regulation of gene expression and often implicated in cancer and inflammatory diseases. By incorporating this moiety into a PROTAC, researchers can effectively degrade BRD4, offering a potential therapeutic strategy for diseases where BRD4 plays a critical role, such as certain cancers and autoimmune disorders. Its application is particularly valuable in drug discovery and development, where it aids in studying BRD4's biological functions and validating it as a therapeutic target. Additionally, it contributes to the exploration of novel treatment approaches that go beyond traditional inhibition, leveraging the body's natural protein degradation machinery for therapeutic benefit.